Open access
Jul 2026
Targeting the adaptor protein Gab1 overcomes MET/Src-driven alectinib resistance in ALK-rearranged NSCLC.
In ALK-positive NSCLC with acquired resistance to alectinib, Gab1 emerged as a crucial downstream signaling convergence target of MET and Src co-activation, and targeting this adaptor protein presented a promising therapeutic strategy to overcome bypass-mediated resistance.
Heng-Yi Chen, Cai-yu Lin, Chen Hu et al.
· Cellular Signalling · 0 citations